David Haen

David Haen


Recent articles

Will Thermo Fisher Buy Qiagen?

Shares of the Dutch diagnostic test manufacturer Qiagen popped after it confirmed ongoing buyout discussions with Thermo Fisher Scientific and others.

Is Exact Sciences Stock a Buy?

Exact Sciences just completed its multibillion-dollar acquisition of Genomic Health, setting the stage for the company’s future.

Is Medtronic a Great Dividend Stock?

Medtronic touts an admirable run of increasing its dividend over 42 consecutive years. But, is the dividend enough for investors to get excited today?

Is Corbus Pharmaceuticals Stock a Buy?

It’s full steam ahead with a slate of late-stage clinical trial results expected in 2020. However, Corbus just release its third quarter results, and the financial picture looks bleak.

4 Stocks Battling Breast Cancer

With Breast Cancer Awareness Month drawing to a close and the San Antonio Breast Cancer Symposium on the horizon, stay alert for breaking news from companies developing new treatments.

Is This Small-Cap Biotech a Buy Before 2020?

Stocks of drug developers, particularly small ones, can skyrocket or crater based on late-stage clinical trials. Before year-end, ChemoCentryx may do one or the other.